



Acquist Therapeutics, Inc.
Essex Fells, NJ 07021

Acquist Therapeutics Completes GLP Animal Studies with Lead Compound

Favorable Results Show Promising Safety and Tolerance

Essex Fells, NJ – September 7, 2021 -- ACQT1127 is a novel drug that has been developed as potential therapy for patients with advanced gout due to elevated uric acid. Acquist Therapeutics, Inc. announced the company has recently completed its late-stage, good laboratory practice (GLP) studies in animals with this compound. Acquist uses GLP studies to evaluate safe dosing parameters for potential human use with the company's clinical drugs.

The animal studies were conducted in rats and monkeys, and both species were treated by oral drug administration (gavage). Each animal group underwent three similar studies using progressively increased drug doses that included: an evaluation of single-dose administration; once-daily, single doses that were administered for a 7-day period; and single doses that were administered once per day for 28 consecutive days.

The studies showed that ACQT1127 was relatively well tolerated in both rat and monkey. There were no drug-related deaths at any dose level in either animal species.

About Acquist Therapeutics: Acquist is a biopharmaceutical company focused on improving health for patients with inflammatory and metabolic diseases. Acquist drugs are potent, patented, bispecific, and orally bioavailable for once-daily dosing. The Acquist clinical lead, ACQT1127, has completed both non-GLP as well as GLP testing and safety in toxicology studies.

Further information can be accessed at: www.acquistrx.com.

SOURCE: Acquist Therapeutics, Inc.®